HCM
ATRA icon

Highbridge Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Highbridge Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-420
Closed -$146K – 1518
2017
Q2 		$146K Buy
+420
New +$162K ﹤0.01% 1150
2016
Q1 		– Sell
-388
Closed -$257K – 1472
2015
Q4 		$257K Buy
+388
New +$293K ﹤0.01% 1246

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's ATRA Position: Q4 2015 in Review

Highbridge Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 331 shares — an estimated $250K sold.

Highbridge Capital Management first reported a position in ATRA in Q3 2015 and held it in 1 quarter. The position peaked at $261K in Q3 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

  • Highbridge Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 331 Atara Biotherapeutics shares in Q4 2015, an estimated $250K.
  • Highbridge Capital Management first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Atara Biotherapeutics position peaked at $261K in Q3 2015.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on Highbridge Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.